Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Project BioShield Mandatory Funding Meets Resistance In House

This article was originally published in The Gray Sheet

Executive Summary

A White House plan to establish a permanent HHS funding stream to contract for bioweapon countermeasures ran into unexpected criticism from a bipartisan group of lawmakers March 27

You may also be interested in...



Bioshield Legislation Headed To Senate Floor Despite Objections Of Sen. Byrd

The Senate sponsors of a bill to authorize Project Bioshield will move the legislation to the floor even if a funding compromise cannot be reached with Senate Appropriations Committee Ranking Member Robert Byrd (D-W.Va.), according Senate HELP Committee staffers

Bioshield Legislation Headed To Senate Floor Despite Objections Of Sen. Byrd

The Senate sponsors of a bill to authorize Project Bioshield will move the legislation to the floor even if a funding compromise cannot be reached with Senate Appropriations Committee Ranking Member Robert Byrd (D-W.Va.), according Senate HELP Committee staffers

Project BioShield Should Exempt Device Firms From Liability – AdvaMed

Liability protections under Project BioShield should be extended to companies that make countermeasure devices and diagnostics available in an emergency situation, AdvaMed says

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018131

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel